l c interview, page-32

Hi all
Been away and now catching up on all this.  I think the issue with the new single  "Complete Response" is:  it's not statistically significant because the overall sample is small.  ie it was a small scale trial.  
But I would also say that to have one of the patients progress to "Complete Response" may not be statistically significant, but it is certainly psychologically very significant.  It really was a small trial, and it is well known that Immunotherapy-thertapy takes time to take effect.  To have someone come through now as "Complete Response" is really a pretty exciting thing.  
Her-Vaxx is intended to train the body to develop an ongoing response.  So the end of dosage is not the end of the story - now we get to see what the body can do after learning the immune response.  They are monitoring the Phase 1b patients ongoing.  More data will come out.
This may be just the start of some very good news.
Time alone will tell, but I'm very glad to be holding and I still regard the current SP as laughably low.
Best wishes to all
Dave